Summary We used data from a large, prospective Canadian cohort to assess the association between selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) and fracture. We found an increased risk of fractures in individuals who used SSRI or SNRI, even after controlling for multiple risk factors. Introduction Previous studies have suggested an association between SSRIs and increasing risk of fragility fractures. However, the majority of these studies were not long-term analyses or were performed using administrative data and, thus, could not fully control for potential confounders. We sought to determine whether the use of SSRIs and SNRIs is associated with increased risk of fragility fracture, in adults aged 50+. Methods We used data from the Canadian Multicentre Osteoporosis Study (CaMos), a prospective randomly selected population-based community cohort; our analyses focused on subjects aged 50+. Time to event methodology was used to assess the association between SSRI/SNRI use, modeled timedependently, and fragility fracture. Results Among 6,645 subjects, 192 (2.9 %) were using SSRIs or/and SNRIs at baseline. During the 10-year study period, 978 (14.7 %) participants experienced at least one fragility fracture. In our main analysis, SSRI/SNRI use was associated with increased risk of fragility fracture (hazard ratio (HR), 1.88; 95 % confidence intervals (CI), 1.48-2.39). After controlling for multiple risk factors, including Charlson score, previous falls, and bone mineral density hip and lumbar bone density, the adjusted HR for current SSRI/SNRI use remained elevated (HR, 1.68; 95 % CI, 1.32-2.14). Conclusions Our results lend additional support to an association between SSRI/SNRI use and fragility fractures. Given the high prevalence of antidepressants use, and the impact of fractures on health, our findings may have a significant clinical impact.
burden [1] . The majority of fractures in adults aged 50 years or older occur following little or no trauma [2] . Low trauma fractures are the hallmark of osteoporosis, a common condition amongst older adults, affecting 21 % of women and 5 % of men over the age of 50 in Canada [3] . Multiple factors have been implicated as increasing the risk of fragility fractures including antidepressant use [4, 5] . Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) use may increase the risk of falls, decrease bone mineral density (BMD), and result in subsequent fractures [6] . Indeed, a recent metaanalysis of 34 studies suggested that SSRIs are associated with a clinically significant increase in the risk of fractures of all types [7] . However, the majority of these studies were not long-term analyses, or were performed using administrative data, and, thus, could not fully control for potential confounders or effect modifiers such as lifestyle habits (smoking, alcohol, and physical activity) and use of other drugs and supplements (e.g., calcium/vitamin D). Moreover, the role of depression in the association between antidepressant use and fracture could not be well explored in most studies, which may be important, since depressed patients may differ from others in terms of both lifestyle factors and use of other drugs and supplements [8] .
Antidepressants are one of the most commonly prescribed class of drugs worldwide [9] . As such, a carefully designed analysis to help further assess the longterm impact of these drugs and the complex relationships between the use of these drugs, current depression, age, and other factors that might themselves independently alter bone density and/or fracture risk is timely. To address these challenges, we sought to determine whether the use of SSRIs or SNRIs is associated with increased risk of fragility fracture.
Methods
The Canadian Multicentre Osteoporosis Study (CaMos) is a prospective randomly selected population-based community cohort examining osteoporosis and fracture risk in noninstitutionalized adults. Our study included those subjects aged 50 or older. Details of CaMos design and data collection procedures have been reported elsewhere [10] . Briefly, recruitment began in February 1996. Participants completed a comprehensive interviewer-administered questionnaire at baseline, which was repeated 5 and 10 years later. The questionnaire was designed to gather information on medical history and fracture-related risk factors, as well as detailed information on current drug use, including dosage, type of drug, route of delivery, and frequency of use.
Outcomes assessment

Fragility fractures
As part of the CaMos protocol, participants were mailed annual questionnaires to ascertain if they had experienced at least one fracture in the previous year [10] . Participants who reported a fracture in the past year completed then a detailed questionnaire that collected data on the type of fracture and its date. Based on this questionnaire, clinical fragility fractures were defined as any fracture that occurred due to a minimal trauma (e.g., falling from bed, chair, or standing height) and were subsequently confirmed by medical or radiographic reports. Follow-up continued for fracture outcomes until the end of the tenth year of the study.
Drug use assessment and modeling
Participants were asked to report current daily drug use, including SSRIs and SNRIs, at baseline (y0), at year 5 (y5), and year 10 (y10) [10] . Interviewers collected detailed drug information, including dosage and frequency of use. When interviews were conducted in participants' homes, all contents of their medicine cabinets were reviewed. When interviews were conducted outside of the participants' homes, they were instructed to bring all of the contents of their medicine cabinets to the interview site. Participants were considered current SSRI users if, at the time of fracture, they were on one or more of citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and SNRI users if they were on venlafaxine. We created time-dependent variables in order to account for changes in SSRI/SNRI use, as well as other antidepressants (tricyclic agents (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin antagonist reuptake inhibitor (SARI), and non-selective monoamine reuptake inhibitors) and other drugs of interest (anxiolytics, antipsychotics, bisphosphonates, antihypertensives, thiazolidinediones, glucocorticoids, and calcium and vitamin D supplements). These drugs were selected because of their potential associations with falls, fractures, depression, or low BMD [11] . We adopted two alternative assumptions for defining timedependent drug exposure (Fig. 1) . For both approaches, if the participant reported being on use of SSRI/SNRI at two adjacent time points (y0 and y5, or y5 and y10), he/she was considered a current user during the entire 5-year period between these two years. In the first approach, drug use was further assumed to be constant for the period covered by each interview; if, for example, a participant reported being on SSRI/SNRI at y0 but neither at y5 nor y10, then he/she was considered current SSRI/SNRI from year 1 to year 4 and a non-user from year 5 to year 10. Using the second approach, if a participant reported being on SSRI/SNRI therapy at the beginning of the 5-year period but not 5 years later, then he/ she was considered a user only in the first year of the period and a non-user in the following 4 years. As part of the second approach, if drug use was reported only at the end of the period but not 5 years earlier, the participant was assumed to be exposed only the last (fifth) year of the corresponding period.
In sensitivity analysis, for participants who interrupted drug use during a given 5-year period, time-dependent exposure was defined as a variable [12] whose time-dependent value gradually decreased from initial value of 1 (in the first year of the period) to 0 in the last year, in equal steps of 0.2 reduction for each additional year. For example, a participant who reported use in year 0 but no use in year 5 was assigned values of 0.8, 0.6, 0.4, and 0.2, respectively, for years 1-4.
In additional analyses, we also examined the effect of these drugs on occurrence of fragility fracture by separating recent versus former use and representing them with two different time-dependent covariates. Specifically, if SSRI/SNRI use was confirmed at each of the two adjacent time points, SSRI/SNRI use was coded as "recent"; but if SSRI/SNRI use was discontinued between two adjacent time points, then use was coded as "recent" only during the first half of the corresponding 5-year period and as "former" for the second half. For instance, if a subject reported being on SSRI/SNRI therapy at year 5, but not at year 10, then he/she was considered as a SSRI/SNRI recent user from year 5 to 7 and a former user from year 8 to 10.
In order to evaluate the effect of dose, SSRI/SNRI doses at baseline were standardized using defined daily doses (DDD), defined as the average maintenance dose per day for a drug used for its main indication in adults [13] . Based on the prescribed medication dosage, the number of tablets, and the frequency of use of each medication, SSRI/SNRI doses were expressed in DDD units.
Covariates
BMD of the lumbar spine (L1-L4), femoral neck, and total hip were measured using dual energy X-ray absorptiometry (DXA) with Hologic QDR 1000, 2000, and 4500 or a Lunar DPX densitometer. All BMD results were converted into the Hologic standard using the method described by Genant et al. [14] . Densitometers were calibrated daily, and quality assurance was performed yearly [10] .
Falls
Fall history was assessed at baseline and at follow-up assessments (years 5 and 10), by self-report. Specifically, participants were asked whether they had fallen in the last month, at the baseline assessment, or in the past year, at the follow-up questionnaires.
Other covariates assessed at baseline were demographic and socioeconomic variables (age, sex, and employment status), lifestyle characteristics (smoking, alcohol intake, and physical activity), comorbidities, and other clinical variables (diagnosis of depression, depressive symptoms, and presence of radiographic vertebral deformities). Alcohol use was reported as the mean number of drinks per week during the past year. Smoking status at baseline was dichotomized as ever use of daily tobacco for at least 6 months (current smoker) versus non-smoker. Regular exercise was defined as participating in a regular exercise program or activity. Depressive symptoms were assessed with the mental health inventory-5 (MHI-5) [15, 16] and the mental component score (MCS) of the short form 36 questionnaire (SF-36) [17] . The presence of depressive symptomatology was defined as a score <42 on the MCS. In sensitivity analyses, we broadened the definition of with the first approach, and from baseline to year 5 for the second approach. SSRI/SNRI was also coded as "recent" from baseline to year 7 and "former" from year 8 onwards, and, finally, it was approximated as a stepwise function in steps of 0.2, for the last drug exposure definition depressive symptoms as having <52 on the MHI-5 scale and/ or <42 on the MCS. Prevalent radiographic-confirmed vertebral deformities were assessed at baseline using a modified Genant's semiquantitative method [18] . This method distinguishes fractured or deformed vertebrae (grades 1, 2, and 3) from normal vertebrae (grade 0). Many Genant grade 1 deformities do not represent true fractures [19] ; we therefore compared two complementary definitions for vertebral fractures: one using Genant grades 2 or 3 and a second using Genant grades 1 to 3. Comorbidities were assessed using a modified version of the Charlson comorbidity [20] based on the following diagnoses: breast cancer, prostate cancer, uterine cancer, dementia, hypertension, kidney disease, hepatic disease, rheumatoid arthritis, myocardial infarction, stroke and transient ischemic attack, types 1 and 2 diabetes mellitus, and chronic obstructive pulmonary disease. All comorbidities were based on the subjects' self-report of diagnoses made by their treating physicians.
Statistical analysis
Time to event methodology was used to assess the association between SSRI/SNRI use and time to first fragility fracture. Event time was defined as time from the baseline interview to the first event. Participants who had no fragility fracture during their follow-up were censored at the earliest of loss to follow-up or end of the study (December 31, 2008) . Main analyses relied on the multivariable Cox proportional hazards regression models, with time-dependent covariates representing the history of SSRI/SNRI exposure (see section on "Drug use assessment and modeling") [21, 22] . The final multivariable Cox model was identified through a combination of a stepwise forward selection of covariates and the Bayesian information criterion (BIC) [23] adopted for censored time-to-event data [24] . Specifically, starting from the initial model that included only indicators of SSRI/SNRI exposure, at each step of forward selection we added the most "significant" of the remaining covariates, i.e., the covariate with the lowest p value for its effect adjusted for all covariates included at the earlier steps, and the resulting change in BIC was computed. The selection process ended when BIC no longer decreased, suggesting the best-fitting multivariable model [24] . Based on the corresponding BIC-optimal multivariable Cox model, we reported the adjusted hazard ratio (HR) and 95 % confidence intervals (CIs) for the relevant measure of SSRI/SNRI exposure. The assumption of proportional hazards (PH) that implies that hazard ratios remain constant over the follow-up time was assessed based on Schoenfeld residuals and tested using the flexible non-PH time-dependent extension of the Cox model [25] .
The analysis of the association between baseline SSRI/SNRI dose and the risk of having any fracture during the first 5 years of study was carried out using multivariable logistic regression. An adjusted odds ratio (OR) for one DDD increase in baseline dose, with 95 % confidence intervals, was estimated after adjusting for the same covariates used in our main analysis.
To test the robustness of our main analyses, in sensitivity analyses, we used multiple imputation [26] for five baseline variables: BMD measurements (total hip, lumbar spine, and femoral neck) and depressive symptoms scales (MCS and MHI-5).
Ethics approval was granted through McGill University and the appropriate research ethics board for each participating center. Signed informed consent was obtained from all study participants in accordance with the Helsinki Declaration [10] .
Results
Overall, 9,423 participants were enrolled in the original CaMos cohort and the current analyses included 6,645 subjects aged over 50 years, who had the baseline BMD measurement. Among those, 5,556 participants (84 %) underwent repeat assessments at year 5 and 4,011 (60 %) completed the full 10 years of follow-up. Characteristics of SSRI/SNRI users and non-users at study baseline and at year 10 are compared in Table 1 . Overall, the distribution of most variables among those who completed the 10-year interview was similar to the entire study population. At baseline, 192 (2.89 %) subjects reported current use of SSRIs or SNRIs; SSRI/SNRI current use increased to 330 (5.94 %) at year 5 and 333 (8.30 %) at year 10. At baseline, compared to non-users, SSRI/SNRI users were more likely to be women, to have more comorbidities, and higher rate of depressive symptoms, but slightly lower prevalence of vertebral deformities (Genant grade ≥1) and use less alcohol. SSRI/SNRI users were also more likely to report previous falls, to have lower BMD at the total hip, and to take psychotropic drugs.
SSRI/SNRI and fragility fractures
During the 10-year study period, 978 participants experienced at least one fragility fracture, including 161 forearm/wrist fractures and 110 rib fractures. In the time-dependent Cox regression model, current use was associated with an increased risk of fragility fracture (HR, 1.88; 95 % CI, 1.48-2.39). This finding was also present in sensitivity analysis, where SSRI/SNRI use was assumed to continue during the entire 5-year period only if the subject reported being on these drugs both at the beginning and at the end of the period (HR, 1.58; 95 % CI, 1.17-2.14). The final model was adjusted for age, sex, education level, Charlson score, smoking, falls in previous month, BMD hip and lumbar, thiazolidinedione use, vitamin D, and previous deformity (Genant grade ≥2). In these 
Dose-effect analysis
This analysis showed that participants taking higher doses of SSRI/SNRI at baseline had a significantly higher risk of fracture (OR for one unit increase in daily defined dose, 1.48; 95 % CI=1.10-1.94). The effect remained statistically significant after adjusting for confounding covariates (OR= 1.41; 95 % CI=1.04-1.88).
Discussion
We examined the relationship between use of SSRIs and SNRIs and fragility fracture incidence among 6,645 men and women aged 50 and older in this large prospective Canadian population-based cohort. After adjustment for potential confounding variables, the association remained statistically significant suggesting an independent effect of SSRI/SNRI on risk of fracture which is consistent with previous studies [4, 5, 7] . In our main analysis, the risk of first fracture was increased by more than 50 % in people currently using SSRI or SNRI (HR=1.68; 95 % CI=1.32-2.15). Our estimate is very similar to a recent meta-analysis of 12 observational studies, which found that the overall risk of fracture was higher among people using SSRI (adjusted odds ratio [OR]= 1.69 and 95 % CI= 1.51-1.90) [27] . Similarly, a Canadian study using the same cohort showed increased fragility fracture risk in SSRI users after 5 years of therapy [4] . Our study extends this observation to a 10-year period, while using time-dependent exposure measures and various sensitivity analyses for the underlying assumptions. Our results also suggest a dose-response relationship between higher SSRI/SNRI doses and increased fracture risk, which is consistent with previously reported findings [5] . Biological mechanisms have been proposed to explain this increased risk of fractures among SSRI and SNRI users. These drugs have an alerting effect, impairing sleep duration and quality and causing insomnia, which may result in daytime [28] . This can contribute to increase the risk of fall, a well-known contributor to fracture risk. Risk of a reported fall has been reported to be increased almost 80 % (adjusted OR=1.79 and 95 % CI=1.45-2.25) in people currently prescribed an SNRI [6] and SSRI (adjusted OR=1.8 and 95 % CI=1.6-2.0) [29] . Several lines of research attest a potential role for the serotonergic system in bone physiology, supporting the hypothesis that SSRIs may have long-term adverse effects on bone health, and therefore increase long-term fracture risk. Functional 5-hydroxytryptamine (5-HT) transporters and receptors are present in osteoblasts, osteocytes, and osteoclasts, and stimulation of these receptors influences bone cell activities [30, 31] . Consistent with this, use of SSRIs, but not tricyclic antidepressants, was associated with increased rates of bone loss at the hip in older women [32] and men [33] . Some studies suggest that SSRIs may be associated with greater risk of fracture than TCAs, postulating a specific serotonergic effect on bone physiology [34, 35] . Another study found that the risk of osteoporotic fracture was significantly higher for current use of antidepressant with a high affinity for 5-HT transporter (all SSRIs agents) compared to those with a medium or low affinity (like TCAs) [36] . In our study, SSRI/SNRI use was associated with lower BMD at baseline for total hip and lumbar spine, which suggests a possible link between these agents and decreased BMD. Despite this evidence, the physiologic mechanism through which SSRI/SNRI use would negatively affect BMD remains speculative [37] . Level of serum C-terminal telopeptide of type I collagen (CTX), a marker of bone turnover, was found associated with serotonin levels in premenopausal women [38] while a large population-based study showed an association of depression status with decreased serum 25(OH) D levels and increased serum parathyroid hormone levels in older subjects [39] . Treatment with one SSRI (escitalopram 10 mg/day) was associated with decreased concentrations of parathyroid hormone and CTX, and increased osteocalcin [40] .
SSRI/SNRI users tend to have more fracture risk factors than the general population; in fact, our baseline analysis showed that SSRI/SNRI users were more likely to be women, have more comorbidities, and more likely to use other antidepressants and anxiolytics, and to have a history of falls. However, the significant association between current SSRI/SNRI and elevated fracture risk remained even after these variables were controlled for in our analysis.
The major strength of the study is that it was populationbased, longitudinal cohort comprising information over a 10-year period, with information on drug exposure and incidence of new fragility fractures. Events of fractures were confirmed by medical or radiographic reports, decreasing the frequency of recall bias or error in patient self-reporting. Furthermore, we were able to control for multiple possible confounding variables which are known to be risk factors for fracture, including falls, bone mineral density, and depression symptoms.
Our study has also some potential limitations. Drug exposure was measured only at three time points, 5 years apart, and we were unable to ascertain if subjects started or stopped the therapy between any two time points. To handle this limitation, we developed several definitions of drug exposure and observed little variation in results across these sensitivity analyses.
Potential confounding by indication should be considered in any observational study of the effects of drugs [8] . Antidepressants are often prescribed for depressive symptoms, and depression itself has been associated with increased risk of fractures [41] . To further address this, we performed analyses controlling for depressive symptoms, using MHI-5 and MCS scales. Previous results on the same cohort showed that depressive symptoms were not independently associated with fragility fractures [42] . This finding, together with our main results, suggests that it may be not only depression but also the antidepressant drugs that induce the excess risk of fractures, at least among SSRI/SNRI users. However, it should be emphasized that depressive symptoms were only measured at discrete time points, i.e., at years 0, 5, and 10 of the followup. Although these scales cannot substitute a clinical diagnosis of depression, they are validated measures of affective health which correlate strongly with depression [15, 43, 44] . Even so, it is possible that the observed association between use of antidepressant and risk of fracture still reflects residual confounding by differences in severity of depression or other unmeasured variables.
Our results may lend additional support to an independent association between SSRI/SNRI use and subsequent fragility fracture. Given the high prevalence of antidepressants use, and the impact of fractures on the health, our findings may have a significant clinical impact. Therefore, physicians treating depressive patients should be aware of potential risk of fractures and discuss with their patients both the benefit/risk ration, as well as some preventive measures the patients could adopt (e.g., in terms of optimizing diet, alcohol use, and exercise, for example). Avoiding co-prescription of other agents that can further affect physical balance and contribute to falls (e.g., anxiolytics) should be also recommended. Additionally, where appropriate, the physician should consider BMD screening for high risk subgroups (particularly older females) with appropriate co-management of fracture risk, such as bisphosphonate use if BMD confirms the need.
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